A data safety monitoring board (DSMB) established in a phase III trial to monitor the safety of participants in a clinical trial views itself as protecting participants and ensuring the integrity of the study. The DSMB should operate under a clear charter, with expectations understood by all members of the Board, the sponsor, and the investigators. Sponsors must trust their DSMBs. The sponsor must give the DSMB the tools and the data that it needs to operate effectively in protecting the safety of the participants.
US Food and Drug Administration.Guidance for clinical trial sponsors: on the establishment and operation of clinical trial data monitoring committees—2001. Available at: http://www.fda.gov/cber/guidelines.htm (accessed September 29, 2004).
SteinbrookR.Improving protection for research subjects.N Engl J Med2002; 346: 1425–30
4.
National Institutes of Health.Clinical trial committee guide. Vol. 8 No. 8. Bethesda, MD: National Institutes of Health; 1979.
5.
EllenbergS.S., FlemingT.R., DeMetsD.L.Data monitoring committees in clinical trials.Chichester (UK): John Wiley And Sons; 2002.
6.
National Institutes of Health.NIH Guide23(11): March 18, 1994.
7.
International Conference on Harmonisation.E9: statistical principles for clinical trials. Available at: http://www.ICH.org (accessed September 29, 2004).
8.
WittesJ.Data safety monitoring boards: a brief introduction.Biopharm Rep2000; 8: 1–7.
